An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

Medicine and Dentistry

• [1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate 100%
• Multiple Myeloma 90%
• Clinical Trial 60%
• Bortezomib 40%
• In Vitro 30%
• Phosphoinositide 3-Kinase Inhibitor 30%
• Patient 30%
• Immunohistochemistry 20%
• Pharmacodynamics 20%
• Tumor Progression 20%
• Tumor Cell 20%
• Antineoplastic Activity 20%
• Hematopoietic System Malignancy 20%
• Neoplasm 10%
• Signal Transduction 10%
• Xenograft 10%
• Cell Proliferation 10%
• Myeloma 10%
• Combination Therapy 10%
• Drug Resistance 10%
• Growth Inhibition 10%
• Phosphoinositide 3-Kinase 10%
• Microvessel 10%
• Tumor Angiogenesis 10%
• Integrin 10%
• Proteasome Inhibitor 10%
• Multiple Myeloma Cell Line 10%
• Survival 10%
• Therapeutic Procedure 10%
• Motivation 10%
• Cell Line 10%

Pharmacology, Toxicology and Pharmaceutical Science

• [1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate 100%
• Multiple Myeloma 90%
• Bortezomib 40%
• Phosphatidylinositol 3 Kinase Inhibitor 30%
• Phase I Trials 30%
• Tumor Growth 20%
• Hematopoietic System Malignancy 20%
• Neoplasm 10%
• Integrin 10%
• Combination Therapy 10%
• Proteasome Inhibitor 10%
• Phosphatidylinositol 3 Kinase 10%
• Nude Mouse 10%
• Myeloma 10%
• Survival 10%

Biochemistry, Genetics and Molecular Biology

• Phosphoinositide 3-Kinase Inhibitor 30%
• Immunostaining 20%
• Antineoplastic Activity 20%
• Pharmacodynamics 20%
• Signal Transduction 10%
• Isoform 10%
• Cell Proliferation 10%
• Nude Mouse 10%
• Proteasome Inhibitor 10%
• Phosphoinositide 3-Kinase 10%
• Angiogenesis 10%
• CD31 10%
• Growth Inhibition 10%
• Drug Resistance 10%
• Growth 10%
• Density 10%
• Motivation 10%
• Survival 10%